Dhaka: Bangladesh’s first home-grown vaccine has received approval from the Bangladesh Medical Research Council (BMRC) for human trials, reported news agency ANI.
Senior manager quality and regulation AT Directorate General of Drug Administration (DGDA) said Bangavax manufacturer Globe Biotech will direct the DGDA human trials protocol, the Daily Star reported.
Following the single-dose vaccine, Bangavax will receive approval for DGDA clinical trials, and Globe Biotech will initiate human trials, the DGDA senior manager said.
Globe Biotech revealed on Oct. 5 last year that its first vaccine candidate had shown promise in preclinical trials on mice, the Daily Star reported.
Bangavax was initially known as Bancovid.
